An FDA advisory panel voted 16 to 4 recommending that KemPharm's (KMPH) Apadaz should be approved for its proposed indication of the management of acute pain that requires an opioid and voted 18 to 2 against inclusion of abuse deterrent labeling for the product.
from RTT - Before the Bell http://ift.tt/21NLEBs
via IFTTT
No comments:
Post a Comment